USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 6,531 shares of the company’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $125.79, for a total transaction of $821,534.49. Following the sale, the insider now directly owns 2,348 shares of the company’s stock, valued at $295,354.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of USANA Health Sciences stock opened at $123.50 on Friday. USANA Health Sciences, Inc. has a twelve month low of $55.50 and a twelve month high of $137.95. The firm has a market cap of $3.05 billion, a P/E ratio of 30.42 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.25. The company had revenue of $301.50 million during the quarter, compared to analysts’ expectations of $278.41 million. USANA Health Sciences had a net margin of 7.16% and a return on equity of 29.50%. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 EPS. analysts anticipate that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current year.

Separately, Pivotal Research reaffirmed a “hold” rating and set a $135.00 price target on shares of USANA Health Sciences in a research report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. USANA Health Sciences has a consensus rating of “Hold” and a consensus target price of $135.00.

Large investors have recently bought and sold shares of the business. Meeder Asset Management Inc. boosted its position in USANA Health Sciences by 675.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 4,914 shares of the company’s stock valued at $567,000 after buying an additional 4,280 shares during the last quarter. Amalgamated Bank purchased a new position in USANA Health Sciences in the 2nd quarter valued at about $223,000. Dupont Capital Management Corp purchased a new position in USANA Health Sciences in the 2nd quarter valued at about $2,263,000. Seizert Capital Partners LLC purchased a new position in USANA Health Sciences in the 1st quarter valued at about $1,913,000. Finally, Engineers Gate Manager LP purchased a new position in USANA Health Sciences in the 2nd quarter valued at about $1,343,000. 56.38% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: What kind of dividend yield to CEF’s pay?

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.